Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey

Icatibant is used to treat acute hereditary angioedema with C1 inhibitor deficiency types I/II (C1‐INH‐HAE types I/II) and has shown promise in angioedema due to acquired C1 inhibitor deficiency (C1‐INH‐AAE). Data from the Icatibant Outcome Survey (IOS) were analysed to evaluate the effectiveness of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Exp Immunol
Autors principals: Longhurst, H. J., Zanichelli, A., Caballero, T., Bouillet, L., Aberer, W., Maurer, M., Fain, O., Fabien, V., Andresen, I.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5343339/
https://ncbi.nlm.nih.gov/pubmed/27936514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.12910
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars